Literature DB >> 14581446

The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time.

Hwan Y Yoo1, Cary H Patt, Jean-Francois Geschwind, Paul J Thuluvath.   

Abstract

PURPOSE: We hypothesized that the outcome of liver transplantation in patients with hepatocellular carcinoma (HCC) has improved over the past decade because of the application of published criteria for patient selection. In this study, we compared the outcome of liver transplantation in patients with and without HCC at different time periods using the United Network for Organ Sharing data. PATIENTS AND METHODS: We excluded children, patients with multiple organ transplantation or retransplantation, and those with incomplete survival data. The study period was arbitrarily divided into three time intervals: 1987 to 1991, 1992 to 1996, and 1997 to 2001.
RESULTS: During the study period, 985 patients with HCC (HCC group), and 33,339 without HCC underwent liver transplantation (control group). Kaplan-Meier patient and graft survivals were significantly lower for the HCC group compared with the control group. Cox regression analysis (after adjusting for other confounding variables) confirmed a lower patient survival in the HCC group (1-year survival, 77.0% v 86.7%; hazard ratio [HR], 1.7; 95% CI, 1.5 to 2.0; P <.0001) compared with the control group (5-year survival, 48.2% v 74.7%; HR, 2.2; 95% CI, 1.9 to 2.4; P <.0001); HCC was an independent predictor of survival. Kaplan-Meier analysis showed a significant improvement in 5-year patient survival with time in patients with HCC (1987 to 1991, 25.3%; 1992 to 1996, 46.6%; 1997 to 2001, 61.1%; P <.0001). During the same period, there was only minimal improvement in survival among the control group.
CONCLUSION: Five-year survival of patients transplanted for HCC is excellent, with a steady improvement in survival over the past decade. It is possible that the published criteria for patient selection may have contributed to the better outcome.

Entities:  

Mesh:

Year:  2003        PMID: 14581446     DOI: 10.1200/JCO.2003.11.137

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  50 in total

Review 1.  Hepatocellular carcinoma: epidemic and treatment.

Authors:  Jill Allen; Alan Venook
Journal:  Curr Oncol Rep       Date:  2004-05       Impact factor: 5.075

Review 2.  Treatment of hepatocarcinoma.

Authors:  Beatrice Gerard; Harry Bleiberg
Journal:  Curr Oncol Rep       Date:  2004-05       Impact factor: 5.075

3.  Impact of preoperative α-fetoprotein level on disease-free survival after liver transplantation for hepatocellular carcinoma.

Authors:  Fabrice Muscari; Jean-Pascal Guinard; Nassim Kamar; Jean-Marie Peron; Philippe Otal; Bertrand Suc
Journal:  World J Surg       Date:  2012-08       Impact factor: 3.352

4.  Orthotopic liver transplantation as a rescue operation for recurrent hepatocellular carcinoma after partial hepatectomy.

Authors:  Zhuo Shao; Rocio Lopez; Bo Shen; Guang-Shun Yang
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

5.  Outcomes Following Resection of Hepatocellular Carcinoma in the Absence of Cirrhosis.

Authors:  Richard H Lewis; Evan S Glazer; David M Bittenbinder; Thomas O'Brien; Jeremiah L Deneve; David Shibata; Stephen W Behrman; Jason M Vanatta; Sanjaya K Satapathy; Paxton V Dickson
Journal:  J Gastrointest Cancer       Date:  2019-12

6.  Surgical treatment of hepatocellular carcinoma with cirrhotic esophageal varices and hypersplenism: a 184 case report.

Authors:  Bin Jiang; Xiaoping Chen; Zhiyong Huang; Zhiwei Zhang; Songqing He; Shaofa Wang; Zaide Wu; Fazu Qiu
Journal:  Front Med China       Date:  2007-02-01

Review 7.  The role of purinergic signaling in the liver and in transplantation: effects of extracellular nucleotides on hepatic graft vascular injury, rejection and metabolism.

Authors:  Guido Beldi; Keiichi Enjyoji; Yan Wu; Lindsay Miller; Yara Banz; Xiaofeng Sun; Simon C Robson
Journal:  Front Biosci       Date:  2008-01-01

8.  Predictive value of CpG island methylator phenotype for tumor recurrence in hepatitis B virus-associated hepatocellular carcinoma following liver transplantation.

Authors:  Li-Ming Wu; Feng Zhang; Lin Zhou; Zhe Yang; Hai-Yang Xie; Shu-Sen Zheng
Journal:  BMC Cancer       Date:  2010-08-02       Impact factor: 4.430

Review 9.  The evolution of liver transplantation for hepatocellular carcinoma (past, present, and future).

Authors:  Yoichi Ishizaki; Seiji Kawasaki
Journal:  J Gastroenterol       Date:  2008-02-24       Impact factor: 7.527

10.  Dual inhibition of Raf and VEGFR2 reduces growth and vascularization of hepatocellular carcinoma in an experimental model.

Authors:  Sven Arke Lang; Isabel Brecht; Christian Moser; Aiman Obed; David Batt; Hans Juergen Schlitt; Edward Kenneth Geissler; Oliver Stoeltzing
Journal:  Langenbecks Arch Surg       Date:  2008-02-23       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.